An update and review of antiretroviral therapy

Pharmacotherapy

Volumn 26, Issue 8 I, 2006, Pages 1111-1133

  Piacenti, Frank J ^a  

^a LINCOLN MEDICAL AND MENTAL HEALTH CENTER   (United States)

Author keywords

Antiretroviral agents; HAART; Highly active antiretroviral therapy; HIV; Human immunodeficiency virus; NRTI; Nucleoside reverse transcriptase inhibitors; Protease inhibitors

Indexed keywords

ABACAVIR; AMINOTRANSFERASE; AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; CISAPRIDE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ERGOT ALKALOID; HYPNOTIC SEDATIVE AGENT; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEUROLEPTIC AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALOPECIA; ANAPHYLAXIS; ANEMIA; AREA UNDER THE CURVE; BLEEDING; BONE MARROW SUPPRESSION; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONCENTRATION LOSS; CONFUSION; COUGHING; DIARRHEA; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; EDEMA; FATIGUE; FATTY LIVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOTENSION; INSOMNIA; KIDNEY FAILURE; LACTIC ACIDOSIS; LETHARGY; LIPODYSTROPHY; LIVER FAILURE; LIVER TOXICITY; META ANALYSIS; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; PANCREATITIS; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; RASH; REVIEW; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TASTE DISORDER; UNPLEASANT DREAM; VIRUS LOAD; VOMITING;

ADENINE; ANIMALS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARBAMATES; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LAMIVUDINE; OLIGOPEPTIDES; PATIENT COMPLIANCE; PEPTIDE FRAGMENTS; PHOSPHONIC ACIDS; PHOSPHORIC ACID ESTERS; PYRIDINES; PYRONES; REVERSE TRANSCRIPTASE INHIBITORS; SULFONAMIDES;

EID: 33746766969     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.8.1111     Document Type: Review

References (67)

1. U.S. Department of Health and Human Services, Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available from www.aidsinfo.nih.gov. Accessed May 10, 2006.
2. U.S. Department of Health and Human Services, Panel on Clinical Practices for Treatment of HIV Infection. Recommendations for use of antretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Available from www.aidsinfo.nih.gov. Accessed April 25, 2005.
3. Smith DM, Wong JK, Hightower GK, et al. HIV drug resistance acquired through superinfection. AIDS 2005;19:1251-6.
4. Smith DM, Richman DD, Little SJ. HIV superinfection. J Infect Dis 2005;192:438-44.
5. Piliero PJ, Young B, Wainberg MA, Turner D, Gallant JE. Current perspectives on the nucleoside/nucleotide components of combination antiretroviral therapy. J Acquir Immune Defic Syndr 2004;37(suppl 1):S1-51.
6. Negredo E, Ruiz L, Paredes R, Fuster D, Molto J, Clotet B. Management of antiretroviral drug resistance in HIV-1 infected patients. In: Business Briefing: Long-Term Healthcare. London, UK: Touch Briefings, 2004:1-7.
7. Meyer PR, Lennerstrand J, Matsuura SE, Larder BA, Scott WA. Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. J Virol 2003;77:3871-7.
8. White KL, Chen JM, Margot NA, et al. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob Agents Chemother 2004;48:922-1003.
9. Prado JG, Parkin NT, Clotet B, Ruiz L, Marinez-Picado J. HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4 T cell counts but persistent virologic failure. Clin Infect Dis 2005;41:729-37.
10. Grim SA, Romanelli F. Tenofovir disoproxil fumarate. Ann Pharmacother 2003;37:849-59.
11. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004;43:595-612.
12. Squires K, Pozniak AL, Pierone G Jr, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003;139:313-20.
13. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 2004;292:191-201.
14. Pruvost A, Negredo E, Benech H, et al. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2005;49:1907-14.
15. Kearney BP, Damle B, Plummer A, Namini H, Ryan K, Cheng A. Pharmacokinetic evaluation of tenofovir DF and enteric-coated didanosine. Presented at the 6th international congress on drug therapy in HIV infection, Glasgow, United Kingdom, November 17-21, 2002.
16. Kunches LM, Reinhalter NE, Marquis A, et al. Tolerability of enteric-coated didanosine capsules compared with didanosine tablets with HIV infection. J Acquir Immune Defic Syndr 2001;28:150-3.
17. Modrzejewski KA, Herman RA. Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor. Ann Pharmacother 2004;38:1006-14.
18. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naïve patients. JAMA 2004;292:180-90.
19. Bang LM, Scott LJ. Emtricitabine: an antiretroviral agent for HIV infection. Drugs 2003;63:2413-26.
20. Nelson M, Schiavone M. Emtricitabine (FTC) for the treatment of HIV infection. Int J Clin Pract 2004;58:504-10.
21. Benson CA, van der Horst C, LaMarca A, et al. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS 2004;18:2269-76.
22. Gilead Sciences, Inc. Truvada (emtricitabine and tenofovir) package insert. Foster City, CA; 2004
23. Dando TM, Wagstaff AJ. Emtricitabine/tenofovir disoproxil fumarate. Drugs 2004;64:2075-82.
24. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. JAMA 2004;292:251-65.
25. Interim 24-week data from study 934 comparing a regimen of Viread and Emtriva versus Combivir, both in combination with Efavirenz, in patients with HIV [press release]. Foster City, CA: Gilead Sciences, Inc.; October 31, 2004.
26. Gathe J, Podzamczer D, Johnson M, et al. Once-daily vs twice-daily lopinavir/ritonavir in antiretroviral-naïve patients: 48 weeks results. Presented at the 11th conference on retroviruses and opportunistic infections, San Francisco, CA, February 8-11, 2004.
27. Gazzard B, DeJesus E, Campo R, et al. The combination of tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) has significantly greater response vs fixed dose zidovudine/lamivudine and EFV in antiretroviral- naïve patients: a 24-week preliminary analysis [abstr]. In: Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2004:H-1137c.
28. Dando TM, Scott LJ. Abacavir plus lamivudine: a review of their combined use in the management of HIV infection. Drugs 2005;65:285-302.
29. GlaxoSmithKline. Epzicom (abacavir and lamivudine) package insert. Research Triangle Park, NC; 2004.
30. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1-infected patients. J Acquir Immune Defic Syndr 2004;35:22-32.
31. MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W. GW433908/ritonavir once daily in antiretroviral therapy-naïve HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 2004;18:651-5.
32. GlaxoSmithKline. Data on file. Research Triangle Park, NC; 2005.
33. Gazzard BG, DeJesus E, Cahn P, et al. Abacavir once daily plus lamivudine in combination with efavirenz is well-tolerated and effective in the treatment of antiretroviral therapy-naïve adults with HIV-1 infection (ZODIAC study: CNA30021) [abstr]. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2003:1722b.
34. DeJesus E, Herrera G, Teolfilo E, et al. Abacavir (300 mg) BID vs zidovudine (300 mg) BID and efavirenz (600 mg) QD in HIV-1 infected, antiretroviral-naïve adults: CNA30024, 48-week final results [abstr]. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2003:H-446.
35. Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J Acquir Immune Defic Syndr 2003;34:S91-4.
36. Plosker GL, Figgitt DP. Tipranavir. Drugs 2003;63:1611-18.
37. Boehringer Ingelheim. Aptivus (tipranavir) package insert. Ridgelfield, CT; 2005.
38. Liebert MA. Antiviral briefs. AIDS Patient Care STDS 2005;19:58-61.
39. Hicks C. RESIST-1: a phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir to an optimized comparator protease inhibitor/r regimen in antiretroviral experienced patients: 24-week data [abstr]. In: Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2004:H-1137a.
40. Schapiro J, Cahn P, Trottier B, et al. Effect of baseline genotype on response to tipranavir/ritonavir compared with standard of care comparator in treatment experienced patients: the phase 3 RESIST-1 and 2 trials. Presented at the 12th conference on retroviruses and opportunistic infections, Boston, MA, February 22-25, 2005.
41. Gallego O, Mendoza C, Corral A, Barrios A, Soriano V. Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitor-experienced patients: implications for tipranavir use. AIDS Patient Care STDs 2005;19:67-9.
42. Chapman TM, Plosker GL, Perry CM. Fosamprenavir: a review of its use in the management of antiretroviral therapy-naïve patients with HIV infection. Drugs 2004;64:2101-24.
43. Nadler J. New anti-HIV protease inhibitors provide more treatment options. AIDS Patient Care STDS 2003;17:551-64.
44. Orrick JJ, Steinhart CR. Atazanavir. Ann Pharmacother 2004;38:1664-74.
45. Kaul S, Bassi K, Damle B, et al. PK of once daily Reyataz, DDI-EC, tenofovir [poster]. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2003:A-1616.
46. Important new pharmacokinetic data for Reyataz (atazanavir) in combination with Viread (tenofovir disoproxil fumarate) [press release]. Rockville, MD: U.S. Food and Drug Administration; August 8, 2003.
47. Bristol-Myers Squibb Company. Reyataz (atazanavir) package insert. Princeton, NJ; 2004.
48. Phair JP. Clinical pharmacology of HIV therapy. Postgraduate Institute for Medicine and Clinical Care Options, LLC, independent coverage of the 6th international workshop on clinical pharmacology of HIV therapy, Quebec City, Quebec, Canada, April 28-30, 2005.
49. Kozal M. Cross-resistance patterns among HIV protease inhibitors. AIDS Patient Care STDS 2004;18:199-208.
50. Havlir Dy O'Marro SD. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis 2004;38:1599-604.
51. Nieto-Cisneros L, Zala C, Fessel WJ, et al. Antiviral efficacy, metabolic changes and safety of atazanavir versus lopinavir/ritonavir in combination with 2 NRTI's in patients who have experienced virologic failure with prior P1-containing regimens: 24 week results from BMS AI424-043. Presented at the 2nd International AIDS Society conference on HIV pathogenesis and treatment, Paris, France, July 13-16, 2003.
52. Lichtenstein K, Clumeck N, Belios N, et al. Lipid benefits are observed in antiretroviral-experienced HIV-infected patients when switched to atazanavir-containing regimens. Presented at the 2nd International AIDS Society conference on HIV pathogenesis and treatment, Paris, France, July 13-16, 2003.
53. Wood R, Phanuphak P, Chan P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004;36:684-92.
54. Duffalo ML, James CW. Enfuvirtide: a novel agent for the treatment of HIV-1 infection. Ann Pharmacother 2003;37:1448-56.
55. Cervia JS, Smith MA. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor. Clin Infect Dis 2003;37:1102-6.
56. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85.
57. (Erratum in N Engl J Med 2003;349:1100.)
58. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95.
59. Shaheen F, Collman RG. Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis 2004;17:7-16.
60. Mascolini M, for the National AIDS Treatment Advocacy Project. ICAAC ART report: new HIV drugs-tipranavir/r; reverset; GSK CCR5 inhibitor 140 news on new(er) antiretroviral. Report 4 from the 14th interscience conference on antimicrobial agents and chemotherapy. Washington, DC, October 30-November 2, 2004.
61. Gazzard BG, Pozniak AL, Rosenbaum W, et al. An open-label assessment of TMC-125, a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003;17:49-54.
62. Katlama C, Ghosn J, Tubiana R, et al. MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase 2 study. AIDS 2004;18:1299-304.
63. Bethell R, Adams J, De Muys J, et al. Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754. Presented at the 11th conference on retroviruses and opportunistic infections, San Francisco, CA, February 8-11, 2004.
64. Murphy RL, Schurmann D, Beard A, et al. Potent anti-HIV-1 activity of reverset following 10 days of monotherapy in treatment-naïve individuals. Presented at the XV international AIDS conference, Bangkok, Thailand, July 11-16, 2004.
65. Katlama C, Berger D, Belios N, et al. Efficacy of TMC114/r in 3-class-experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. Presented at the 12th conference on retroviruses and opportunistic infections, Boston, MA, February 22-25, 2005.
66. Olson W, Israel R, Jacobson J, et al. Viral resistance and pharmacologic analysis of phase I/II study patients treated with HIV-1 entry inhibitor PRO 542. Presented at the 10th conference on retroviruses and opportunistic infections, Boston, MA, February 10-14, 2003.
67. Martin D, Jacobson J, Schurmann D, et al. PA-457, the first-in-class maturation inhibitor, exhibits antiviral activity following a single dose in HIV-1 infected patients. Presented at the 12th conference on retroviruses and opportunistic infections, Boston, MA, February 22-25, 2005.